An aptamer‐based magnetic resonance imaging contrast agent for detecting oligomeric amyloid‐β in the brain of an Alzheimer's disease mouse model
Sign Up to like & getrecommendations! Published in 2022 at "NMR in Biomedicine"
DOI: 10.1002/nbm.4862
Abstract: The oligomeric amyloid‐β (oAβ) is a reliable feature for an early diagnosis of Alzheimer's disease (AD). Therefore, the objective of this study was to demonstrate imaging of oAβ deposits using our developed DNA aptamer called… read more here.
Keywords: contrast agent; gddota ob5; contrast; oligomeric amyloid ... See more keywords
A calcium-sensitive antibody isolates soluble amyloid-β aggregates and fibrils from Alzheimer’s disease brain
Sign Up to like & getrecommendations! Published in 2022 at "Brain"
DOI: 10.1093/brain/awac023
Abstract: Abstract Aqueously soluble oligomers of amyloid-β peptide may be the principal neurotoxic forms of amyloid-β in Alzheimer’s disease, initiating downstream events that include tau hyperphosphorylation, neuritic/synaptic injury, microgliosis and neuron loss. Synthetic oligomeric amyloid-β has… read more here.
Keywords: alzheimer disease; oligomeric amyloid; disease brain; amyloid ... See more keywords
Quantitative assessment of oligomeric amyloid β peptide binding to α7 nicotinic receptor
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Pharmacology"
DOI: 10.1111/bph.14688
Abstract: Progressive dysfunction of cholinergic transmission is a well‐known characteristic of Alzheimer's disease (AD). Amyloid β (Aβ) peptide oligomers are known to play a central role in AD and are suggested to impair the function of… read more here.
Keywords: peptide; amyloid peptide; quantitative assessment; assessment oligomeric ... See more keywords